LeMaitre to Participate in Upcoming Investor Conferences
LeMaitre Vascular (Nasdaq:LMAT) announced management will participate in three investor conferences in Nov–Dec 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LeMaitre Vascular (Nasdaq:LMAT) announced management will participate in three investor conferences in Nov–Dec 2025.
- Jefferies London Healthcare Conference — Tuesday, November 18, 2025 at 8:00 AM GMT at Waldorf Hilton, London; presenter: Dorian LeBlanc, CFO.
- Wolfe Research 7th Annual Healthcare Conference — Wednesday, November 19, 2025 at 10:40 AM ET at Wolfe NYC Offices, New York; presenter: David Roberts, President.
- Piper Sandler 37th Annual Healthcare Conference — Thursday, December 4, 2025 at 3:20 PM ET at Lotte Palace, New York; presenter: Dorian LeBlanc, CFO.
Details
News Market Reaction – LMAT
On Nov 13, the first trading day after this news, LMAT closed 0.37% below the previous close.
Data tracked by StockTitan Argus for the Nov 13 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
Jefferies London Healthcare Conference 2025
Tuesday, November 18, 2025
Waldorf Hilton, London
Dorian LeBlanc, CFO, will present at 8:00 AM GMT
Wolfe Research 7th Annual Healthcare Conference
Wednesday, November 19, 2025
Wolfe NYC Offices, New York, NY
David Roberts, President, will present at 10:40 AM ET
Piper Sandler 37th Annual Healthcare Conference
Thursday, December 4, 2025
Lotte Palace, New York, NY
Dorian LeBlanc, CFO, will present at 3:20 PM ET
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. For more information about the Company, please visit www.lemaitre.com.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc.
Contact:
Sandra Millar
LeMaitre Vascular, Inc.
+1-781-425-1686
smillar@lemaitre.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.